Mounjaro®
Starting from £179.99/mo
Start journey Learn moreYes, a BMI of 27 can qualify you for Mounjaro (tirzepatide), but only if you also have at least one weight-related health condition. The medicine's UK licence covers adults with a BMI of 27 or above alongside a qualifying comorbidity such as type 2 diabetes, high blood pressure, or high cholesterol. BMI alone is not enough, and a prescriber makes the final decision after a full clinical assessment. These are prescription-only medicines, so a genuine consultation — reviewing your full health picture — is required before any treatment can be issued.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
It does. Tirzepatide's UK marketing authorisation permits prescribing for adults with a BMI of 30 or above, or a BMI of 27 or above when at least one weight-related comorbidity is present. That second threshold is the relevant one here. The NHS tirzepatide medicines page sets out the licensed indications clearly, and the prescribing information confirms both BMI bands.
What counts as a qualifying comorbidity? The list includes type 2 diabetes, prediabetes, high blood pressure, dyslipidaemia (raised cholesterol or triglycerides), obstructive sleep apnoea, and osteoarthritis, among others. If you have a formal diagnosis of any of these, a BMI of 27 puts you inside the licensed criteria for Mounjaro on paper. That said, paper criteria are the starting point, not the finish line. A prescriber will still assess your wider health, any contraindications, and whether treatment is appropriate for you specifically.
It is also worth knowing that UK guidance acknowledges different average body compositions across ethnic groups. For people from South Asian, Chinese, Middle Eastern, Black African, or African-Caribbean backgrounds, clinical thresholds are often set 2.5 kg/m² lower, meaning the bar is easier to meet at a BMI of 27. The full breakdown of BMI requirements for Mounjaro covers these nuances in more detail.
This is the scenario where the answer shifts. Without a weight-related comorbidity on record, a BMI of 27 does not currently meet the UK licensed threshold for tirzepatide. The licence is unambiguous on this point: the lower BMI band only applies alongside a qualifying diagnosis. A prescriber cannot legitimately issue a Mounjaro prescription for weight management alone at BMI 27, and any service offering to do so without satisfying this requirement would be acting outside the licensed indications.
If you are unsure whether a condition you have qualifies, that is exactly the kind of question a structured consultation is designed to answer. Conditions are sometimes diagnosed during the assessment process itself, particularly blood pressure and cholesterol readings that a person was not previously aware of. Our general FAQs address some of the more common eligibility questions if you want to read further before booking.
People with a BMI slightly above or below 27 sometimes ask about adjacent thresholds, there is a separate look at the evidence for whether Mounjaro is available at BMI 25 if that is closer to your situation.
The NHS criteria for tirzepatide are considerably stricter than the private licensed criteria. NICE's appraisal of tirzepatide (TA1026, published December 2024) recommends it on the NHS for adults with a BMI of 35 or above alongside at least one qualifying condition, within a phased rollout through specialist services. At BMI 27, NHS access is not available under current guidance.
Private prescribing follows the medicine's licensed criteria directly, which is why a BMI of 28 with a comorbidity, or indeed 27, can be clinically appropriate through a regulated private pharmacy. There is no waiting list, no referral needed, and no requirement to meet the higher NHS thresholds. The consultation happens the same day; a named prescriber reads your answers and medical history personally, not software. If you are approved, your treatment is dispatched the same working day (orders placed by 12pm Monday to Friday) and arrives free the next working day via DPD in plain packaging.
For context on what private treatment costs at different stages, the Mounjaro cost page explains what goes into private pricing and what a transparent single price should include. Worth reading before comparing providers.
At BMI 27, the consultation tends to focus particularly on confirming the comorbidity that brings you into licensed range. You will be asked about your medical history, current diagnoses, any medicines you take, and relevant lifestyle factors. Live weight verification means our prescribers can confirm your BMI rather than relying on a self-reported figure, an important step when the threshold matters as much as it does here.
If you are on other medicines, your prescriber will check for any interactions or considerations. For example, people asking whether they can get Mounjaro at a BMI of 27 sometimes also want to know about combining it with certain blood pressure medicines; our prescribers can discuss that specifically during assessment. Identity is verified with photo ID as a standard step, and a GP notification is sent in line with GPhC guidance so your wider care team is informed.
Our clinical team brings specialist prescribing experience to every review. No consultation is a box-ticking exercise, if treatment is not right for you, that will be explained clearly, with guidance on what the appropriate next step looks like. If you would like to understand the process before starting, the treatment overview page gives a plain-English summary of what to expect.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.